Department of Radiology, Nippon Medical School, Tokyo.
J Radiat Res. 2011;52(3):365-8. doi: 10.1269/jrr.10159. Epub 2011 Apr 14.
A study was conducted to evaluate the early results of high-dose-rate superficial brachytherapy (HDR-SB) after keloidectomy. Between April 2008 and April 2009, 21 patients with 36 histologically confirmed keloids were treated with postoperative HDR-SB. The tube applicator was placed on the skin to match the area of the surgical wound, and a spacer 5 mm thick was placed between the skin and the applicator. A dose evaluation point was established below 2 mm from skin surface, and 20 Gy was delivered in 4 daily fractions to keloidectomy scars on the anterior chest wall, scapular region, lower jaw and suprapubic region. A dose of 15 Gy was delivered in 3 daily fractions to lesions in other areas. The median follow-up period was 18 months (range, 9 to 29 months). Therapeutic outcome was judged in terms of recurrence, control, or acute side effects. Three keloids (9.7%) in two patients showed local recurrence, with a median time to failure after HDR-SB of 12 months. All recurrences affected the anterior chest wall. Dysraphia occurred in only one patient with an anterior chest wall lesion. Excluding the cases of recurrence, acceptable cosmetic results were achieved. Our results indicate that HDR-SB is effective and safe for preventing recurrence of keloids.
一项研究旨在评估切除瘢痕疙瘩后高剂量率浅层放射治疗(HDR-SB)的早期结果。2008 年 4 月至 2009 年 4 月,21 例 36 例经组织学证实的瘢痕疙瘩患者接受了术后 HDR-SB 治疗。将管敷贴器放置在皮肤上,与手术伤口的区域相匹配,在皮肤和敷贴器之间放置 5 毫米厚的间隔物。在距皮肤表面 2 毫米以下建立剂量评估点,并在前胸壁、肩胛区、下颌和耻骨区的瘢痕疙瘩手术切除部位给予 20 Gy 的 4 次每日分割剂量。在其他部位的病变给予 15 Gy 的 3 次每日分割剂量。中位随访时间为 18 个月(范围为 9 至 29 个月)。根据复发、控制或急性副作用来判断治疗效果。2 例 3 例(9.7%)瘢痕疙瘩患者出现局部复发,HDR-SB 后中位失败时间为 12 个月。所有复发均影响前胸壁。只有一名前胸壁病变患者出现发音困难。排除复发病例后,达到了可接受的美容效果。我们的结果表明,HDR-SB 对于预防瘢痕疙瘩复发是有效且安全的。